Related Experiment Video
Updated: Jul 13, 2026
11:17
Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer
Published on: February 27, 2026
Extrapulmonary small cell carcinoma: single center experience with 61 patients
Sung Sook Lee1, Jae-Lyun Lee, Min-Hee Ryu
1Division of Oncology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Acta Oncologica (Stockholm, Sweden)
|July 27, 2007
Summary
Extrapulmonary small-cell carcinoma (EPSCC) survival is poor, with limited treatment options and high recurrence rates, especially for gastrointestinal primary tumors. Further clinical trials are essential to develop effective treatment strategies for EPSCC.
Area of Science:
- Oncology
- Pathology
Background:
- Extrapulmonary small-cell carcinoma (EPSCC) is a rare malignancy distinct from lung small-cell carcinoma.
- Understanding its clinico-pathologic features and prognostic factors is crucial for patient management.
Purpose of the Study:
- To review the clinico-pathologic features of EPSCC.
- To evaluate treatment modalities and survival outcomes in EPSCC patients.
- To identify prognostic factors for survival in EPSCC.
Main Methods:
- Retrospective review of medical records of 61 EPSCC patients diagnosed between January 1995 and July 2004.
- Analysis of primary tumor sites, disease status (limited vs. extensive), treatment received, and survival data.
- Univariate analysis to identify prognostic factors for overall survival (OS).
Main Results:
- The most common primary sites were the gastrointestinal (GI) tract (56%) and uterine cervix (18%).
- Median overall survival was 16 months; 1- and 3-year OS rates were 59% and 29%.
- Advanced disease status was a significant negative prognostic factor for OS (p<0.001). GI primary tumors had poorer prognoses than other sites.
Conclusions:
- EPSCC treatment response and survival outcomes are generally discouraging.
- Surgery followed by adjuvant therapy in limited disease SCC showed high rates of recurrence and metastasis.
- Clinical trials are urgently needed to establish optimal treatment strategies for EPSCC.
